A University Institutional Biosafety Committee (IBC) has been created in accordance with requirements set forth in the National Institutes of Health "Guidelines for Research Involving Recombinant DNA Molecules". All research investigations involving Recombinant DNA, infectious agents or oncogenic materials or agents must be registered with the UBC. All work involving recombinant DNA that is subject to the current NIH Guidelines must be reviewed and approved by the IBC before such work can begin.
In order to expedite the processing of applications and to
provide appropriate, deliberate review of proposals, the committee
has developed additional guidelines which are specific to its
needs. Each investigator contemplating initiation of such work must
adhere to the following:
After IBC has received all documents requested, it may be
expected that the following steps will take place for proposed
When research is first initiated, rules for observing the proper
BL level of containment must be posted in the laboratory. Any
changes in the names, addresses and phone numbers of persons
employed in laboratories engaged in these studies must be reported
to the Secretary of the IBC.
Training of Laboratory Personnel: It is the prime responsibility of the PI to provide instruction regarding specific techniques for research and dangers of materials to be handled and to document this training. It is the responsibility of the PI to be certain that all technical personnel are familiar with these sections of the NIH Laboratory Safety Monograph and the Biosafety in Microbiological and Biomedical Laboratories (5th Edition) that pertain to techniques being employed. The PI can obtain assistance in these matters from EH&S. It is recommended that all technical personnel and students attend courses on general laboratory safety organized by EH&S.
Reinspection of Facilities: The Biosafety Officer will make periodic inspections of major equipment items such as biological safety hoods, autoclaves, etc., in order to insure proper containment of agents being used.
Health Surveillance: Beyond the minimum requirements stated in the NIH Guidelines for the reporting of extended illnesses and accidents, the PI may initiate other measures such as those discussed in the NIH Laboratory Safety Monograph. Examples of such additional measures could include periodic physical and medical examinations or collection and maintenance of serum samples. The health status of a laboratory worker may place that person at increased risk in any endeavor where infectious agents are handled. Examples given in the Laboratory Safety Monograph include gastrointestinal disorders and treatment with steroids, immunosuppressive drugs or antibiotics. Workers with such disorders or treatment should be evaluated to determine whether they should be engaged in research with potentially hazardous organisms during their treatment or illness. The IBC will determine the necessity, in connection with each project, for health surveillance of recombinant DNA research personnel, and conduct, if found appropriate, a health surveillance program for the project.
The following procedures must be observed for making changes in an on-going research program:
Meetings of the IBC will be open to the public, provided
sufficient notice is given to the chairman so that adequate meeting
space can be obtained. Only those parts of meetings dealing with
privileged information (i.e., technical details of grant
applications that have not been approved and funded) will remain
closed. EH&S will maintain, for public viewing, minutes of
committee meetings, information about future meetings, a lay
summary of each recombinant DNA proposal submitted by principal
investigators, and a list of reference material helpful to an
understanding of the procedures involved in studies of recombinant